(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Exploring the Gig Economy: Examples from Consultants - 2Eleven arrested over mass shooting in South Africa tavern
- 3New Jordan security fence could be done in early 2028
- 4Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
- 5Hypothermia claims newborn in Gaza and more babies are at risk, doctor says
- Instructions to Comprehend and Use Open Record Extra Offers
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- Must-See Attractions in Washington, D.C.
- Vote in favor of your Number one Kind of Gems
- 6 Useful Home Espresso Machines
- Different Film Classification: What's Your Go-To for Amusement
- Astronomers detect black hole blasting winds at incredible speeds
- Staggering Spots to Stargaze All over the Planet
- Recalled "super greens" supplement linked to dozens of salmonella cases, CDC says
